AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00650949
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
Trial: NCT02799082
Drug: BF-200 ALA
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
Trial: NCT01772953
Drug: Treosulfan
RxNorm normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
Trial: NCT00144573
Drug: MRA(Tocilizumab)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02038738
Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04364997
Drug: Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
Trial: NCT04364997
Drug: Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
Trial: NCT04364997
Drug: Duloxetine Hydrochloride Enteric-coated Capsule Placebo
RxNorm normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
Trial: NCT04364997
Drug: Duloxetine Hydrochloride Enteric-coated Capsule
RxNorm normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
Trial: NCT02181231
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
Trial: NCT02181231
Drug: buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
Trial: NCT00103649
Drug: xaliproden (SR57746A)
RxNorm normalized name: xaliproden
DrugBank: Xaliproden (DB06393)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01805297
Drug: Intravitreal Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One time 2.0mg aflibercept injection, following pars plana vitrectomy.
Trial: NCT00357305
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00357305
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00357305
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02288429
Drug: colistimethate sodium
RxNorm normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01979653
Drug: dexmedetomidine alone or dexmedetomidine + midazolam
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01175226
Drug: BTA798
RxNorm normalized name: BTA798
DrugBank: BTA798 (DB05181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTA798 twice daily
Trial: NCT00087074
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00835406
Drug: Alendronate Sodium Tablets 70mg
RxNorm normalized name: Alendronate Sodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 70mg, single dose fasting
Trial: NCT03344861
Drug: Porfimer Sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
Trial: NCT00398112
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT01573702
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg once daily
Trial: NCT00499889
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg by mouth twice daily for 9 Days
Trial: NCT00499889
Drug: Fludarabine (Fludara)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 by vein daily for 4 Days
Trial: NCT00499889
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2 by vein daily for 2 Days
Trial: NCT00499889
Drug: Antithymocyte Globulin (ATG)
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg by vein daily for 3 Days
Trial: NCT00499889
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
Trial: NCT01978184
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01978184
Drug: abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01978184
Drug: hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01438190
Drug: Metformin, gonadotropins in step-down regimen
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
Trial: NCT02369133
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
Trial: NCT02261116
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02261116
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02752048
Drug: TAS-205
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
Trial: NCT03568916
Drug: Apixaban (ATC B01AF02)
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Trial: NCT03568916
Drug: Dabigatran (ATC B01AE07)
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Trial: NCT03568916
Drug: Rivaroxaban (ATC B01AF01)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Trial: NCT02605590
Drug: AIR DNase
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06038682
Drug: Argatroban Injection
RxNorm normalized name: argatroban Injection
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
Trial: NCT01431508
Drug: Losartan 50 mg / HCTZ 12.5 mg
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
Trial: NCT00132769
Drug: MK-0873
RxNorm normalized name: MK-0873
DrugBank: MK-0873 (DB13029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0873 1.25 mg twice daily for 12 weeks
Trial: NCT03049059
Drug: 4% hydroquinone cream
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01609556
Drug: Mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
Trial: NCT03099382
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
Trial: NCT03099382
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
Trial: NCT01108744
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol 20% intravenous solution, dosed by patient's ideal body weight
Trial: NCT01802411
Drug: EXPAREL 266 mg
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00185445
Drug: Fludarabine Phosphate (Fludara)
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
Trial: NCT02985190
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine at 75mg/m²/j for 7 days.
Trial: NCT02728843
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg tablets
Trial: NCT02826226
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00333216
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior juxtascleral administration of suspension
Trial: NCT00333216
Drug: Anecortave Acetate Sterile Suspension, 60 mg/ML
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior juxtascleral administration of suspension
Trial: NCT01956305
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg tablet for Cohort F
Trial: NCT01413490
Drug: rimantadine
RxNorm normalized name: Rimantadine
DrugBank: Rimantadine (DB00478)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
Trial: NCT01676831
Drug: Topical resiquimod 0.06%
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
Trial: NCT01676831
Drug: topical resiquimod 0.03%
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
Trial: NCT01364064
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
Trial: NCT03196765
Drug: Sobetirome (NV1205)
RxNorm normalized name: Sobetirome
DrugBank: Sobetirome (DB07425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day oral dose of the study drug
Trial: NCT00090012
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00090012
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00125554
Drug: Metyrapone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00999830
Drug: IPH2101
DrugBank: IPH 2101 (DB06049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One infusion of IPH2101 every 4 weeks
Trial: NCT00522210
Drug: Detemir
RxNorm normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
Trial: NCT01343706
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release solid oral dosage (film-coated tablet)
Trial: NCT01343706
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for oral administration
Trial: NCT00003200
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02376413
Drug: Chemotherapy or endocrine therapy or Trastuzumab therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02103686
Drug: Lyrica
RxNorm normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00412256
Drug: Omegaven (10% fish-oil emulsion; Fresenius-Kabi)
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00138216
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00138216
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00138216
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04781075
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given at the beginning of the surgery for post-operative pain management
Trial: NCT02562625
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Powder solution for infusion
Trial: NCT03124459
Drug: ACE-083
RxNorm normalized name: albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
Trial: NCT00282243
Drug: tacrolimus modified release (MR)
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00282243
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03453892
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Trial: NCT03453892
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Trial: NCT03453892
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Trial: NCT00317044
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily
Trial: NCT00317044
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily
Trial: NCT00851903
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
Trial: NCT00851903
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration. 100mg film-coated tablets.
Trial: NCT00851903
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Trial: NCT00430118
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00430118
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00430118
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00430118
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00430118
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00430118
Drug: vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00270894
Drug: epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
Trial: NCT00270894
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
Trial: NCT00270894
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
Trial: NCT00320970
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04647110
Drug: crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: as provided in real world practice